Form 4: UNITED THERAPEUTICS CEO Sells Shares
Insider Transaction (Form 4)
Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 10, 2026.
Summary
- Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 10, 2026; holds 50,013 after (Direct).
- Open-market sale: disposed of 600 Common Stock at $540.37 ($324,223) on July 10, 2026; holds 49,413 after (Direct).
- Open-market sale: disposed of 970 Common Stock at $541.47 ($525,226) on July 10, 2026; holds 48,443 after (Direct).
- Open-market sale: disposed of 1,870 Common Stock at $542.49 ($1,014,451) on July 10, 2026; holds 46,573 after (Direct).
- Open-market sale: disposed of 676 Common Stock at $543.34 ($367,296) on July 10, 2026; holds 45,897 after (Direct).
- Open-market sale: disposed of 364 Common Stock at $544.54 ($198,212) on July 10, 2026; holds 45,533 after (Direct).
- Open-market sale: disposed of 1,524 Common Stock at $545.54 ($831,409) on July 10, 2026; holds 44,009 after (Direct).
- Open-market sale: disposed of 1,438 Common Stock at $546.42 ($785,750) on July 10, 2026; holds 42,571 after (Direct).
- Open-market sale: disposed of 1,578 Common Stock at $547.17 ($863,440) on July 10, 2026; holds 40,993 after (Direct).
- Open-market sale: disposed of 400 Common Stock at $548.44 ($219,375) on July 10, 2026; holds 40,593 after (Direct).
- Open-market sale: disposed of 80 Common Stock at $553.47 ($44,278) on July 10, 2026; holds 40,513 after (Direct).
- Option exercise/conversion: disposed of 9,500 Stock Option on July 10, 2026; holds 20,718 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,173,660 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Martine A Rothblatt — Director, Officer (Chairperson & CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-10 | Option exercise/conversion | Common Stock | 9,500 | $135 | $1.3M | 50,013 |
| 2026-07-10 | Open-market sale | Common Stock | 600 | $540 | $324.2K | 49,413 |
| 2026-07-10 | Open-market sale | Common Stock | 970 | $541 | $525.2K | 48,443 |
| 2026-07-10 | Open-market sale | Common Stock | 1,870 | $542 | $1.0M | 46,573 |
| 2026-07-10 | Open-market sale | Common Stock | 676 | $543 | $367.3K | 45,897 |
| 2026-07-10 | Open-market sale | Common Stock | 364 | $545 | $198.2K | 45,533 |
| 2026-07-10 | Open-market sale | Common Stock | 1,524 | $546 | $831.4K | 44,009 |
| 2026-07-10 | Open-market sale | Common Stock | 1,438 | $546 | $785.8K | 42,571 |
| 2026-07-10 | Open-market sale | Common Stock | 1,578 | $547 | $863.4K | 40,993 |
| 2026-07-10 | Open-market sale | Common Stock | 400 | $548 | $219.4K | 40,593 |
| 2026-07-10 | Open-market sale | Common Stock | 80 | $553 | $44.3K | 40,513 |
| 2026-07-10 | Option exercise/conversion | Stock Option | 9,500 | — | — | 20,718 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-10 | Option exercise/conversion (9,500 shares) |
| 2026-07-10 | Open-market sale (600 shares) |
| 2026-07-10 | Open-market sale (970 shares) |
| 2026-07-10 | Open-market sale (1,870 shares) |
| 2026-07-10 | Open-market sale (676 shares) |
| 2026-07-10 | Open-market sale (364 shares) |
| 2026-07-10 | Open-market sale (1,524 shares) |
| 2026-07-10 | Open-market sale (1,438 shares) |
| 2026-07-10 | Open-market sale (1,578 shares) |
| 2026-07-10 | Open-market sale (400 shares) |
| 2026-07-10 | Open-market sale (80 shares) |
| 2026-07-10 | Option exercise/conversion (9,500 shares) |
Keywords
insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.